TAR-200 for Treatment of BCG-Unresponsive, High-Risk NMIBC

An expert discusses how the SunRISe-1 phase 2b trial, presented at the European Society for Medical Oncology 2024 Congress (ESMO 2024), evaluated TAR-200 alone and with cetrelimab in BCG-unresponsive, high-risk non–muscle invasive bladder cancer (NMIBC). TAR-200 monotherapy achieved an 84% complete response rate, with most adverse events being mild to moderate. The combination therapy showed higher rates of severe adverse events. TAR-200 is particularly promising for patient’s ineligible for or refusing radical cystectomy.

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 4:55

Loaded: 3.33%

0:00

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -4:55

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

• en (Main), selected

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EP: 1.Drug Delivery Systems in NMIBC

Now Viewing

EP: 2.TAR-200 for Treatment of BCG-Unresponsive, High-Risk NMIBC

EP: 3.Adoption of Emerging Delivery Systems and Future Outlook for NMIBC

Video content above is prompted by the following:

• The results of the SunRISe-1 phase 2b clinical trial, which investigated the use of the TAR-200 delivery system alone vs with cetrelimab, were recently presented at ESMO 2024.
• What are your impressions of the safety and efficacy data?
• Which patients might be the best candidates for the TAR-200 delivery system based on this data?

Related Videos

Adoption of Emerging Delivery Systems and Future Outlook for NMIBC

Drug Delivery Systems in NMIBC